Previous 10 | Next 10 |
- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Company anticipates topline, interim data for RSV lead program IVX-121 in 2Q 2022 - ...
Gainers: Clever Leaves Holdings (CLVR) +33%. NextDecade (NEXT) +23%. Dynagas LNG (DLNG) +23%. Clarus Therapeutics (CRXT) +23%. Amylyx (AMLX) +20%. Hoegh LNG Partners LP (HMLP) +21%. Kidpik (PIK) +19%. Agrify (AGFY) +17%. NexImmune (NEXI) +17%. Joby Aviation (JOBY) +17%. Losers: Icosavax (ICVX...
Gainers: Clever Leaves (CLVR) +28%. Tilray Brands (TLRY) +13%. Cutera (CUTR) +11%. STRATA Skin Sciences (SSKN) +10%. Clarus Therapeutics (CRXT) +8%. Losers: MEI Pharma (MEIP) -58%. Icosavax (ICVX) -50%. Rezolute (RZLT) -9%. Alpha Tau Medical (...
Clinical-stage biotech, Icosavax (NASDAQ:ICVX), has lost ~20% in the pre-market Friday after reporting topline interim data from its ongoing Phase 1/2 clinical trial for IVX-411, a COVID-19 vaccine candidate. While the vaccine candidate was generally well tolerated, the level of the...
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology; end-to-end drug product investigation underway - - Data indicate favorable preli...
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced that the company will participate in the Cowen ...
Newly IPO’ed biotech company Icosavax (ICVX +12.3%) has recorded the biggest intraday gain since early December after Janus Henderson Group reported nearly 5% stake in the company. According to a 13-F filing submitted on Monday, the London-based asset manager has bought more than 1.8M ...
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milesto...
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of John Shiver, Ph.D., to its Bo...
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies - Adds Mike Powell, Ph.D., as Executive Partner & promotes Francesco Draetta to Partner PR Newswire BOSTON , Dec. 17, 2021 /PRNewswire/ -- Omega F...
News, Short Squeeze, Breakout and More Instantly...
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
NEW YORK, NY / ACCESSWIRE / February 1, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: AVROBIO, Inc. (NASDAQ:AVRO)'s merge...
2024-01-09 00:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...